Bioconjugates such as antibody–drug conjugates have rapidly expanded into a major therapeutic class, yet clinical setbacks continue to reveal challenges in managing drug-to-antibody ratio, linker stability, and overall product consistency. These issues highlight the need for a clear understanding of how conjugation chemistry, linker design, and payload choice shape a bioconjugate’s behavior — and for new strategies that can address these interconnected design hurdles.
Download this whitepaper to learn:
- Core design challenges in modern bioconjugates
- How conjugation strategies shape bioconjugate stability and efficacy
- Advances in linker and payload design that expand development options
